Highlights Zymeworks Inc.

Equities

ZYME

US98985Y1082

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-28 EDT			5-day change	1st Jan Change
8.51 ^USD	+1.19%		+1.19%	-18.09%

06-17	Zymeworks Says FDA Clears Investigational New Drug Application for Cancer Therapy	MT
06-17	Zymeworks Gets FDA OK to Study ZW171 for Mesothelin-Expressing Cancers	DJ

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Zymeworks Inc. Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer	06-10	CI
Sector Update: Health Care Stocks Decline Premarket Monday	06-10	MT
Zymeworks Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-02	CI
Zymeworks Inc. Presents New Data from Multiple Preclinical Development Programs At 2024 American Association for Cancer Research Annual Meeting	04-08	CI
Zymeworks Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-06	CI
Zymeworks Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-06	CI
Zymeworks Inc. to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting	03-05	CI
Zymeworks Appoints Jeffrey Smith as Chief Medical Officer; Cash Runway Extended	01-04	MT
Zymeworks Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-07	CI
Zymeworks Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Jazz Pharmaceuticals plc and Zymeworks Inc. Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers	23-06-02	CI
Zymeworks Inc. Enters into License and Collaboration Agreement with Jazz Pharmaceuticals Ireland Limited	23-05-16	CI
Zymeworks Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-08	CI
Zymeworks Inc. Announces New Data from its Clinical and Preclinical Development-Stage Programs at the 2023 American Association for Cancer Research Annual Meeting	23-04-18	CI
Zymeworks Terminates Research, Development, Commercialization Agreement with Daiichi Sankyo	23-03-20	MT
Zymeworks Posts Q4 Profit As Revenue Jumps; Shares Rise After-Hours	23-03-07	MT
Zymeworks Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-07	CI
Earnings Flash (ZYME) ZYMEWORKS Reports Q4 EPS $4.71	23-03-07	MT
Zymeworks Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-07	CI
Jazz Pharmaceuticals and Zymeworks Announces 84% Overall Survival At 18 Months from Phase 2 Trial Evaluating Zanidatamab in Her2-Expressing Metastatic Gastroesophageal Adenocarcinoma	23-01-19	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Zymeworks Inc.

Equities

ZYME

US98985Y1082

Highlights

Filters